StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
0RF7.IL$51.63-6.79%
Fair $51.63+0.0%

0RF7.IL

Humana AB (publ)

Healthcare / Medical Care FacilitiesIOB

$51.63

-3.75 (-6.79%)

Fairly Valued+0.0%Fair Value $51.63Fund rank 34/100 · Data gapFallback financials|
SA 59/C
F-Score: 8/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 23% · confianza 25%

FCF escenarios

weak_data · normalized FCF $770.0M · quality 67.7/100

Data gap 34/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 85/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

59/100

C

Piotroski

8/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 0RF7.ILLocal privado en este navegador · Humana AB (publ)
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$2.5B

P/E

9.5x

↓

EV/EBITDA

6.0x

↓

ROE

7.6%

↑

Gross Margin

95.7%

↑

Debt/Equity

1.41

↑
52-Week Range$52
$33$56

TradingView lightweight chart

0RF7.IL price, volumen y niveles de valoración

Último $55.25Periodo -20.4%
Fair value: $51.63

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+2.9%

FCF CAGR

+6.7%

FCF margin

7.7%

FCF / Net income

3.26x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $10.02B · net income $236.0M · FCF $770.0M

2022-FY → 2025-FY

Gross margin

95.7%+0.4% pts

Operating margin

4.6%+0.1% pts

Net margin

2.4%+0.1% pts

FCF margin

7.7%+0.8% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$10.02B$10.02B$10.30B$9.64B$9.20B
Net Income$236.0M$236.0M$144.0M$176.0M$210.0M
EBITDA$1.11B$1.11B$1.06B$1.02B$897.0M
EPS4.734.732.873.724.37
Gross Margin95.7%95.7%95.4%95.1%95.3%
Operating Margin4.6%4.6%4.9%3.9%4.5%
Net Margin2.4%2.4%1.4%1.8%2.3%
Balance Sheet
Debt/Equity1.411.411.631.871.97
Current Ratio1.051.05———
Cash Flow
Free Cash Flow$770.0M$770.0M$869.0M$621.0M$633.0M
Returns
ROE7.6%7.6%4.6%6.1%7.7%
Valuation
P/E9.549.5412.657.279.20
EV/EBITDA5.975.976.015.927.40
P/B0.830.830.580.450.70
Growth & Yield
Revenue Growth-2.7%-2.7%6.8%4.8%—
EPS Growth64.8%64.8%-22.8%-14.9%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

-1.1%

fácil

EPS terminal req.

$4.58

Spread vs growth

65.9%

5Y implied EPS CAGR

3.2%

fácil

EPS terminal req.

$5.54

Spread vs growth

61.6%

10Y implied EPS CAGR

6.6%

razonable

EPS terminal req.

$8.93

Spread vs growth

58.3%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +43.8%

Total return

+43.8%

Start / end P/E

12.5x → 10.9x

EPS bridge

2.87 → 4.73

Residual

-8.3%

EPS growth+64.8%
Multiple rerating-12.8%
Dividend+0.0%
Residual / FX / buybacks / cross-term-8.3%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.